View Message in Browser

[link removed]

 

[link removed]

 

[link removed]

 

[link removed]

 

mailto:[email protected]

[link removed]

**The Latest Research, Commentary, and News from Health Affairs**

**Tuesday, November 19, 2019**

[link removed]

TODAY ON THE BLOG

PAYMENT

Private Equity And Powerful Physician Groups Raise Another Distraction

By Hunter Kellett, Alexandra Spratt, and Mark E. Miller

Congress can help close a damaging loophole in the health care system by
bringing everyone to the negotiating table. Read More >>

PHARMACEUTICALS & MEDICAL TECHNOLOGY

Toward Continuous Evidence-Based Treatment For Opioid Use Disorder:
Lessons from North Carolina

By Aaron McKethan, Hilary Campbell, Andrew Olson, Susan Kansagra, Elyse
Powell, and Emma Sandoe

We aim to draw attention, both within and beyond North Carolina, to
learning that can increase the rate at which people with OUD receive
appropriate, ongoing, evidence-based treatment. These findings are
relevant for North Carolina and, we believe, instructive for state and
federal policy making as we explore ways to make further progress
related to the opioid epidemic. Read More >>

IN THE JOURNAL

PHARMACEUTICALS & MEDICAL TECHNOLOGY

Little Consistency In Evidence Cited By Commercial Plans For Specialty
Drug Coverage

By James D. Chambers, Ari D. Panzer, Elle F. Pope, Jennifer S. Graff,
and Peter J. Neumann

Researchers have reported wide variation in how commercial health
insurance plans cover specialty drugs, which suggests that a patient's
health plan can determine their access to these treatments. James
Chambers and coauthors used information from the Tufts Medical Center
Specialty Drug Evidence and Coverage Database to examine the evidence
that plans reported reviewing in specialty drug coverage policies. Read
More >>

Biosimilar Filgrastim Uptake And Costs Among Commercially Insured,
Medicare Advantage

By Pinar Karaca-Mandic, Jessica Chang, Ronald Go, Stephen Schondelmeyer,
Daniel Weisdorf, and Molly Moore Jeffery

Pinar Karaca-Mandic and coauthors report on the uptake and costs of the
first biosimilar in the US market, filgrastim-sndz (Zarxio). Following
rapid uptake, by March 2018 filgrastim-sndz accounted for 47 percent of
filgrastim administrations among the commercially insured and 42 percent
among Medicare Advantage beneficiaries. Read More >>

Read the November 2019 Table of Contents

****

Subscribe to Health Affairs

**for full journal access**

[link removed]

HEALTH AFFAIRS EVENTS-PAST EVENT:  MILITARY HEALTH SYSTEMS

The August 2019 issue of Health Affairs examines the Military Health
System and the pressures and opportunities that are similar to those in
the civilian sector. Get caught up with the Military Health Systems
event:  slides

(click on Download Event), video
, and
podcast
.

Access the August PRINT

or ONLINE

issue.

Getevent-specific emails
delivered directly to your inbox.

A CLOSER LOOK-Youth Mental Health

****

****Most American parents say that they might have trouble
distinguishing between a teen's typical mood swings and possible signs
of depression, a new survey published Monday finds. This Health Affairs
Blog post from 2015 argues that health care systems and schools must
place high priority onearly screening and prevention of mental health
problems in youth
.

[link removed]

[link removed]

 

[link removed]

 

[link removed]

 

[link removed]

About Health Affairs

Health Affairs is the leading peer-reviewed journal
at the intersection of health,
health care, and policy. Published monthly by Project HOPE, the journal
is available in print and online. Late-breaking content is also found
through healthaffairs.org , Health Affairs
Today , and Health Affairs
Sunday Update .  

Project HOPE is a global health and
humanitarian relief organization that places power in the hands of local
health care workers to save lives across the globe. Project HOPE has
published Health Affairs since 1981.

Copyright © Project HOPE: The People-to-People Health Foundation, Inc.

Health Affairs, 7500 Old Georgetown Road, Suite 600, Bethesda, MD 20814, United States

Privacy Policy

To unsubscribe from this email, click here
.                 
                                               
                        I